how do i purchase via a Roth IRA

Hi John, in order to invest via your Roth IRA, you will have to work directly with your IRA provider to facilitate your transaction. For more details, you can always reach out to support@wefunder.com.

Arrive AI(ARAI ON NASDAQ). Does anyone know the Stock Transfer Agent? I would like to transfer my shares to my brokerage account.

Hi Clinton, please reach out to support@wefunder.com for help with questions about transfer agents.

Now that the first funding Goal was met, will my investment still be evaluated at the $6.41/share price listed in the information details?

Hi Timothy, yes, all investments in our community round will get the $6.41/share price listed, regardless of what day you come into the round.

Hi, I do not find a maximum mentioned anywhere for this raise. Is it a round $1M or is there no ceiling at all?

Hi Josh, the maximum for this raise is $5M.

Hi! I'm fairly new to investing so I had a question about the initial funding round. Is what's being offered here that investors can contribute now, and then later purchase stock (at the rate of $6.41 per share), thus making two investments?

Hi Hannah! Not quite. What's being offered now to everyone and for the entire duration of the round is the purchase of preferred shares at $6.41 per share. So, only one investment, and everyone is getting the same terms whether you come in today or weeks from now. Everyone receives the same terms, regardless of when they join. Hope that helps clarify!

Siren Biotechnology Updates, Team, and Funding Progress | Wefunder, Home of the Community Round

$28M raised from leading VCs including Founders Fund, Lux Capital, and more

Fighting the world’s second deadliest disease, cancer, with AAV immuno-gene therapy

Led by expert doctors and scientists from Stanford, UCSF, Duke, Mount Sinai, and Roche

2025 Start Up of The Year winner at Phacilitate Advanced Therapies Week

$4M in competitive grant awards from the California Institute for Regenerative Medicine (CIRM)

Targeting clinical trials in 2026, a critical step toward FDA approval and commercialization

The global brain tumor therapeutics market is a $3.2B market

CEO featured in The Wall Street Journal, The Economist, WIRED, MIT Tech Review, and Boston Globe

Siren Biotechnology

Turning deadly cancers into treatable diseases, backed by Founders Fund

$4,058,119

Updates

Siren Biotechnology

Quick facts

Team profiles

Featured investor profiles

$4,058,119

Updates